Background
The rat anti-mouse CD8b monoclonal antibody YTS 156.7 (rat IgG2b kappa) reacts with the mouse CD8b protein (T-cell surface glycoprotein CD8 beta chain, Lyt-3 or Ly-3) encoded by the mouse cd8b gene that encodes the CD8b chain of the dimeric CD8 protein. The mouse CD8 protein is primarily responsible for cell-mediated immune defense and T-cell development.
Our recombinant YTS 156.7 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse CD8b monoclonal antibody (hybridoma clone name or number: YTS 156.7).
PA007382.r2b: In vivo Grade Recombinant Anti-mouse CD8b Monoclonal Antibody, Rat IgG2b Kappa (Clone: YTS 156.7)
The in vivo grade recombinant anti-mouse CD8b rat IgG2b monoclonal antibody was produced in mammalian cells.
Clone: YTS 156.7.
Isotype: Rat IgG2b kappa.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: 156.7) specifically binds to mouse CD8b.
Applications: Western blot, immunohistochemistry (IHC), Flow Cytometry (FC), and in vivo CD8+ T cell depletion.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.
Shipping: The in vivo grade recombinant anti-mouse CD8b antibodies (clone of YTS 156.7) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-mouse CD8b antibody (YTS 156.7)
Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING.
Wang L, et al. (2023). Journal for ImmunoTherapy of Cancer. 11(8):e006235. doi: 10.1136/jitc-2022-006235. PMID: 37640480
In some experiments, CD8 + T cells were depleted by injecting 200 μg/mouse of anti- CD8 α antibodies (clone 2.43, ATCC) or anti- CD8 β (clone YTS 156.7.7, ECACC European collection of cell cultures) antibodies i.p. 2 days before hRT, on the day of the first hRT, and once weekly thereafter. B16- CD133 and MC38 tumor cell suspensions were mixed with Matrigel (Corning) at 1:1 ratio and injected s.c. into the right flank (primary tumor) and left flank (secondary tumor) of C57BL/6N mice aged 6–8 weeks. The primary tumor received two consecutive fractions of local hypofractionated RT (hRT) of 12 Gy (B16- CD133) or three fractions of 8 Gy (MC38) when the primary and secondary tumors reached a volume of 200–350 mm3 and 75–120 mm3, respectively (approximately day 10 after primary tumor inoculation). As shown in figure 2B–D, the effect of triple therapy on both primary and secondary tumor was reduced when CD8 + cells were depleted by either anti- CD8 α or anti- CD8 β antibodies. In mice with bilateral non- targeted control MC38 tumors, hRT/ α PD- 1/ Doxil triple therapy slowed the growth and cured some of the nonirradiated tumors (as in mice bearing parental MC38 WT tumors (see figure 1E)).
Tags: anti-mouse CD8b; YTS 156.7 antibody
Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.
Heiler S, et al. (2018). Front Immunol. 9:656. doi: 10.3389/fimmu.2018.00656. PMID: 29670626
In order to obtain donor cell suspensions depleted of CD8 + T cells, DBA/2 mice were injected i.v. with 200 μl of 1 mg/ml YTS-156, a rat anti-mouse mAb specific for CD8 β, 4 days before the mice were used to prepare cell suspensions. GvHD was induced by i.v. injection of 70 × 10^6 DBA/2 lymphocytes in a volume of 200 μl SF-IMEM. The high efficiency of in vivo donor CD8 + T cell depletion was confirmed by flow cytometry analysis of the donor lymphocyte preparation (data not shown). To test this, cGvHD was induced by transfer of donor lymphocytes from DBA/2 mice previously injected with the CD8 β-depleting mAb YTS-156. Analysis of IFN-γ production in untreated cGvHD mice showed that CD8 + T cells of both, donor and host origin, were highly activated irrespective of the time point of the analysis after disease induction.
Tags: anti-mouse CD8b YTS 156.7 antibody in vivo; anti-mouse CD8b YTS 156.7 in animal model
Robo4 vaccines induce antibodies that retard tumor growth.
Zhuang X, et al. (2015). Angiogenesis. 18(1):83-95. doi: 10.1007/s10456-014-9448-z. PMID: 25348086
Depletion of the CD8 + T cell subset in mice D epletion of CD8 + T cells from Fc or Robo4 - Fc vaccinated mice was initiated 14 days post - immunisation. I n brief, 200 μg of rat anti - mouse CD8 ( an equal concentration of YTS 169 anti - mouse CD8 alpha and YTS 156.7.7 anti - mouse CD8 beta, kindly supplied by Professor Steve Cobbold , Therapeutic Immunology Group, Sir William Dunn School of Pathology, University of Oxford , UK ) was injected intraperitoneal ly per mouse every third days for the duration of the experiment ( 19 , 20 ) . To determine the role of cytotoxic T cells in the anti - tumor effect , CD8 + T cells were depleted by i njection of antibodies 14 days after Robo4 - Fc or Fc immunisation. Efficient depletion was verified by flow cytometry of peripheral blood cells from the vaccinated mice ( Supplemental figure 5 ). This showed that in the absence of CD8 + T cells the therapeutic effect of Robo4 vaccinat ion was unchanged , arguing against a role for cytotoxic T cells in the inhibition of tumor growth ( Figure 4 c ).
Tags: anti-mouse CD8b YTS 156.7 antibody in cancer research; function of anti-mouse CD8b YTS 156.7
Effects of T-lymphocyte depletion on muscle fibrosis in the mdx mouse.
Morrison J, et al. (2005). Am J Pathol. 166(6):1701-10. doi: 10.1016/S0002-9440(10)62480-7. PMID: 15920155
Seven and nine days after the thymectomy, each mouse received intraperitoneal injections of CD4 (YTS 191.1.2 and YTA 3.1.2) or CD8 (YTS 156.7.7 and YTS 169.4.7) antibodies or both together. To investigate the role of T lymphocytes in fibrosis, we depleted either CD4 or CD8 or both subsets of T lymphocytes from 4-week-old mdx mice by use of thymectomy followed by specific antibody, administration 7 and 9 days after thymectomy. Mice that had less than 2.5% circulating or splenic CD4 cells were grouped together and represent the highest CD4-depleted animals, which was equivalent to more than 97.5% depletion. Overall results showed that hydroxyproline levels in the diaphragm of CD4, CD8, or CD4/8 double-depleted mdx mice were indistinguishable from those seen in untreated mdx. In both single- and double-depleted mdx and C57BL/10 mice, some T lymphocytes were still present within the diaphragm.
Tags: bioactivity of anti-mouse CD8b YTS 156.7 antibody; anti-mouse CD8b YTS 156.7 mAb of low endotoxin
Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription.
Muir A, et al. (1995). J Clin Invest. 95(2):628-34. doi: 10.1172/JCI117707. PMID: 7860747
Synergistic depleting monoclonal antibodies against CD4+ (YTS 191.1 and YTA 3.1.2) and CD8+ (YTS 169.4 and YTS 156.7, anti-mouse CD8b) T lymphocytes were kindly provided by Dr. Anne Cooke (Cambridge University, UK). Starting 1 wk after completing a two-dose immunizing course of B-chain insulin at 4 and 8 wk of age, one intravenous dose followed by two intraperitoneal monoclonal antibody or control treatments were administered. These were given 7, 5, and 3 d before the animals were killed. In vivo depletion of CD4+ and CD8+ lymphocytes. Depletion of either CD4+ or CD8+ T lymphocytes before transfer abrogated the ability of B-chain-immunized splenocytes to prevent the transfer of diabetes (P < 0.01).
Tags: anti-CD8b clone YTS 156.7; clone YTS 156.7 of anti-mouse CD8b antibody
For more references about anti-mouse CD8b antibody (YTS 156.7), please contact our scientific support team with message@sydlabs.com.
Related Recombinant IgG Reference Antibodies:
In vivo grade recombinant rat IgG2b isotype control antibody
Syd Labs provides the following recombinant anti-human CD8a monoclonal antibodies:
In vivo grade recombinant anti-human CD8a antibodies (clone OKT8)
Recombinant anti-human CD8a antibodies (clone OKT8) for flow cytometry
Syd Labs provides the following recombinant anti-mouse CD8a monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8a antibodies (clone 2.43)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 169.4)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 105.18)
Syd Labs provides the following recombinant anti-mouse CD8b monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8b antibodies (clone YTS 156.7)